X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CC-42344 is a novel, broad-spectrum PB2 inhibitor, investigational antiviral candidate, which is being evaluated for the treatment of pandemic and seasonal influenza A.
Lead Product(s): CC-42344
Therapeutic Area: Infections and Infectious Diseases Product Name: CC-42344
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Details:
CC-42344 is a novel, broad-spectrum PB2 inhibitor, investigational antiviral candidate, which is being evaluated for the treatment of pandemic and seasonal influenza A.
Lead Product(s): CC-42344
Therapeutic Area: Infections and Infectious Diseases Product Name: CC-42344
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2023
Details:
CC-42344 is a oral small molecule PB2 inhibitor which is being evaluated for the treatment of pandemic and seasonal influenza A in phase 2 clinical trials.
Lead Product(s): CC-42344
Therapeutic Area: Infections and Infectious Diseases Product Name: CC-42344
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
CDI-988, a novel, oral, broad-spectrum 3CL protease inhibitor, receives HREC approval to conduct a Phase 1 study for the potential treatment for COVID-19.
Lead Product(s): CDI-988
Therapeutic Area: Infections and Infectious Diseases Product Name: CDI-988
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
CDI-988, a novel, oral, broad-spectrum 3CL protease inhibitor, receives HREC approval to conduct a Phase 1 study for the potential treatment for COVID-19.
Lead Product(s): CDI-988
Therapeutic Area: Infections and Infectious Diseases Product Name: CDI-988
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
The proceeds will be used in its influenza A program, in which the Company is preparing to file with the United Kingdom regulatory agency to begin a Phase 2a human challenge study with its oral PB2 inhibitor CC-42344.
Lead Product(s): CC-42344
Therapeutic Area: Infections and Infectious Diseases Product Name: CC-42344
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Phillip Frost
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 10, 2023
Details:
In vitro testing showed CC-42344’s excellent antiviral activity against influenza A strains, including pandemic and seasonal strains, as well as against strains resistant to Tamiflu® and Xofluza®, while also demonstrating favorable PK and safety profiles.
Lead Product(s): CC-42344
Therapeutic Area: Infections and Infectious Diseases Product Name: CC-42344
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
CC-42344, an oral PB2 inhibitor, is specifically designed to be effective against all significant pandemic and seasonal influenza A strains and to have a high barrier to resistance due to the way the virus’ replication machinery is targeted.
Lead Product(s): CC-42344
Therapeutic Area: Infections and Infectious Diseases Product Name: CC-42344
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
CC-42344 is an oral PB2 inhibitor, is specifically designed to be effective against all significant pandemic and seasonal influenza A strains and to have high barrier to resistance due to the way the virus’ replication machinery is targeted.
Lead Product(s): CC-42344,Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: CC-42344
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
Details:
CC-42344 is an oral PB2 inhibitor specifically designed to be effective against all significant pandemic and seasonal influenza A strains and to have a high barrier to resistance due to the way the virus’ replication machinery is targeted.
Lead Product(s): CC-42344
Therapeutic Area: Infections and Infectious Diseases Product Name: CC-42344
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
